E76.21 Morquio mucopolysaccharidoses

Name of the Condition

• Morquio mucopolysaccharidoses (ICD-10 Code: E76.21)

Summary

Morquio mucopolysaccharidoses are a rare inherited disorder characterized by the accumulation of glycosaminoglycans (GAGs) due to enzyme deficiencies. This buildup disrupts normal cellular function, leading to progressive multisystem involvement, including skeletal abnormalities, organ enlargement, and neurological impairment. Early recognition and management are important to address complications and slow disease progression.

Causes

The disorder is caused by genetic mutations that impair enzymes responsible for breaking down glycosaminoglycans. These mutations result in the accumulation of undegraded GAGs in cells, tissues, and organs, disrupting normal structure and function. The specific enzyme deficiency determines the type and severity of the condition.

Risk Factors

• Family history of mucopolysaccharidoses or related lysosomal storage disorders.
• Consanguineous relationships (increased risk of recessive inheritance).
• Ethnic or geographic populations with higher carrier rates for specific mutations.

Symptoms

• Skeletal abnormalities, such as short stature, joint stiffness, or dysostosis multiplex.
• Organ enlargement (e.g., hepatosplenomegaly).
• Neurological symptoms, including developmental delay, seizures, or cognitive impairment.
• Coarse facial features, clouded corneas, and respiratory complications.

Diagnosis

Diagnosis involves clinical evaluation, biochemical testing to measure enzyme activity, and genetic testing to identify mutations. Imaging studies may reveal skeletal abnormalities, and urine tests can detect elevated GAG levels. Early diagnosis is critical for initiating timely management.

Treatment Options

Treatment focuses on managing symptoms and complications, including enzyme replacement therapy, physical therapy, and surgical interventions for skeletal or organ issues. Multidisciplinary care involving specialists in genetics, orthopedics, and neurology is often required.

Prognosis and Follow-Up

Prognosis varies depending on the severity of the condition and the specific enzyme deficiency. Regular follow-up with healthcare providers is essential to monitor disease progression, manage complications, and adjust treatment plans as needed.

Complications

Complications may include severe skeletal deformities, respiratory insufficiency, cardiac valve disease, and progressive neurological impairment. Early intervention can help mitigate these risks.

Lifestyle & Prevention

While the condition is inherited, supportive care such as physical therapy, assistive devices, and respiratory support can improve quality of life. Genetic counseling is recommended for families to understand inheritance patterns and recurrence risks.

When to Seek Professional Help

Seek medical attention if symptoms such as unexplained joint pain, developmental delays, or organ enlargement are observed. Prompt evaluation is important for early diagnosis and management.

Tips for Medical Coders

When coding for Morquio mucopolysaccharidoses (E76.21), ensure documentation supports the diagnosis, including clinical findings, enzyme testing, or genetic confirmation. Verify that the code aligns with the specific subtype and any associated complications to ensure accurate reporting.